General Information:
Id: | 7,308 |
Diseases: |
Alzheimer disease
- [OMIM]
Metabolic |
Homo sapiens | |
article/cited | |
Reference: | Couttas TA et al.(2014) Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimers disease pathogenesis Acta Neuropathol Commun 2: 9 [PMID: 24456642] |
Interaction Information:
Comment | Sphingosine 1-Phosphate Phosphatases 1 and 2 (SGPP1 and SGPP2) specifically catalyse the dephosphorylation of S1P. |
Formal Description Interaction-ID: 71690 |
|
Comment | Sphingosine 1-Phosphate Phosphatases 1 and 2 (SGPP1 and SGPP2) specifically catalyse the dephosphorylation of S1P. |
Formal Description Interaction-ID: 71691 |
|
Comment | S1P levels decline during AD pathogenesis in human hippocampus (A), inferior temporal GM (B), inferior temporal WM (C), superior frontal GM (D), superior frontal WM (E), and cerebellum. |
Formal Description Interaction-ID: 71692 |
disease decreases_quantity of drug/chemical compound |
Comment | ApoE regulates secretion of the potent neuroprotective signaling lipid Sphingosine 1-phosphate (S1P). S1P is derived by phosphorylation of sphingosine, catalysed by sphingosine kinases 1 and 2 (SphK1 and 2), and SphK1 positively regulates glutamate secretion and synaptic strength in hippocampal neurons(cited information). Hippocampal S1P level is related to APOE genotype. |
Formal Description Interaction-ID: 71693 |
gene/protein affects_quantity of drug/chemical compound |
Drugbank entries | Show/Hide entries for APOE |
Comment | ApoE regulates secretion of the potent neuroprotective signaling lipid Sphingosine 1-phosphate (S1P). S1P is derived by phosphorylation of sphingosine, catalysed by sphingosine kinases 1 and 2 (SphK1 and 2), and SphK1 positively regulates glutamate secretion and synaptic strength in hippocampal neurons. (cited information) |
Formal Description Interaction-ID: 71694 |
drug/chemical compound increases_activity of |
Comment | S1P is derived by phosphorylation of sphingosine, catalysed by sphingosine kinases 1 and 2 (SphK1 and 2), and SphK1 positively regulates glutamate secretion and synaptic strength in hippocampal neurons. (cited information) |
Formal Description Interaction-ID: 71695 |
gene/protein increases_quantity of drug/chemical compound |
Comment | ApoE regulates secretion of the potent neuroprotective signaling lipid Sphingosine 1-phosphate (S1P). S1P is derived by phosphorylation of sphingosine, catalysed by sphingosine kinases 1 and 2 (SphK1 and 2), and SphK1 positively regulates glutamate secretion and synaptic strength in hippocampal neurons. (cited information) |
Formal Description Interaction-ID: 71696 |
gene/protein increases_quantity of drug/chemical compound |
Comment | SphK1 positively regulates glutamate secretion and synaptic strength in hippocampal neurons. (cited information) |
Formal Description Interaction-ID: 71697 |
|
Comment | SphK1 positively regulates glutamate secretion and synaptic strength in hippocampal neurons. (cited information) |
Formal Description Interaction-ID: 71698 |
|
Comment | S1P is essential for development of the neural tube and vascular system during embryogenesis. It is a potent cytoprotective factor that has been shown to protect cultured cortical neurons against Abeta toxicity. Signalling through pre-synaptic S1P3 receptors, S1P also stimulates glutamate secretion in hippocampal neurons, promoting long-term potentiation and memory consolidation. Similarly SphK1 localised to pre-synaptic terminals is required for neurotransmitter release and charge transfer in response to acetylcholine stimulation. (cited information) |
Formal Description Interaction-ID: 71699 |
drug/chemical compound increases_activity of process |
Comment | S1P is essential for development of the neural tube and vascular system during embryogenesis. It is a potent cytoprotective factor that has been shown to protect cultured cortical neurons against Abeta toxicity. Signalling through pre-synaptic S1P3 receptors, S1P also stimulates glutamate secretion in hippocampal neurons, promoting long-term potentiation and memory consolidation. Similarly SphK1 localised to pre-synaptic terminals is required for neurotransmitter release and charge transfer in response to acetylcholine stimulation. (cited information) |
Formal Description Interaction-ID: 71700 |
drug/chemical compound increases_activity of process |
Comment | S1P is essential for development of the neural tube and vascular system during GO:0001944. It is a potent cytoprotective factor that has been shown to protect cultured cortical neurons against Abeta toxicity. Signalling through pre-synaptic S1P3 receptors, S1P also stimulates glutamate secretion in hippocampal neurons, promoting long-term potentiation and memory consolidation. Similarly SphK1 localised to pre-synaptic terminals is required for neurotransmitter release and charge transfer in response to acetylcholine stimulation. (cited information) |
Formal Description Interaction-ID: 71701 |
|
Comment | S1P is essential for development of the neural tube and vascular system during embryogenesis. It is a potent cytoprotective factor that has been shown to protect cultured cortical neurons against Abeta toxicity. Signalling through pre-synaptic S1P3 receptors, S1P also stimulates glutamate secretion in hippocampal neurons, promoting long-term potentiation and memory consolidation. Similarly SphK1 localised to pre-synaptic terminals is required for neurotransmitter release and charge transfer in response to acetylcholine stimulation. (cited information) |
Formal Description Interaction-ID: 71702 |
drug/chemical compound decreases_activity of gene/protein |
Comment | S1P is essential for development of the neural tube and vascular system during embryogenesis. It is a potent cytoprotective factor that has been shown to protect cultured cortical neurons against Abeta toxicity. Signalling through pre-synaptic S1P3 receptors, S1P also stimulates glutamate secretion in hippocampal neurons, promoting long-term potentiation and memory consolidation. Similarly SphK1 localised to pre-synaptic terminals is required for neurotransmitter release and charge transfer in response to acetylcholine stimulation. (cited information) |
Formal Description Interaction-ID: 71703 |
drug/chemical compound increases_quantity of drug/chemical compound |
Comment | S1P is essential for development of the neural tube and vascular system during embryogenesis. It is a potent cytoprotective factor that has been shown to protect cultured cortical neurons against Abeta toxicity. Signalling through pre-synaptic S1P3 receptors, S1P also stimulates glutamate secretion in hippocampal neurons, promoting long-term potentiation and memory consolidation. Similarly SphK1 localised to pre-synaptic terminals is required for neurotransmitter release and charge transfer in response to acetylcholine stimulation. (cited information) |
Formal Description Interaction-ID: 71704 |
drug/chemical compound increases_activity of process |
Comment | S1P is essential for development of the neural tube and vascular system during embryogenesis. It is a potent cytoprotective factor that has been shown to protect cultured cortical neurons against Abeta toxicity. Signalling through pre-synaptic S1P3 receptors, S1P also stimulates glutamate secretion in hippocampal neurons, promoting long-term potentiation and memory consolidation. Similarly SphK1 localised to pre-synaptic terminals is required for neurotransmitter release and charge transfer in response to acetylcholine stimulation. (cited information) |
Formal Description Interaction-ID: 71705 |
drug/chemical compound increases_activity of process |
Comment | S1P is essential for development of the neural tube and vascular system during embryogenesis. It is a potent cytoprotective factor that has been shown to protect cultured cortical neurons against Abeta toxicity. Signalling through pre-synaptic S1P3 receptors, S1P also stimulates glutamate secretion in hippocampal neurons, promoting long-term potentiation and memory consolidation. Similarly SphK1 localised to pre-synaptic terminals is required for neurotransmitter release and charge transfer in response to acetylcholine stimulation. (cited information) |
Formal Description Interaction-ID: 71706 |
|
Comment | Loss of S1P proceeds in tandem with the development of NFT (neurofibrillary tangles) pathology, coupled to a decline in the activity of sphingosine kinases, which catalyse S1P synthesis. |
Formal Description Interaction-ID: 71707 |
drug/chemical compound decreases_quantity of phenotype |
Comment | Over 99% of AD cases are the age-related, late onset form of the disease, for which the greatest genetic risk factor is the APOE4 allele. Apolipoprotein E (ApoE) is a major lipid transport protein of the central nervous system (CNS) that also mediates the transport and clearance of Abeta. Homozygous carriers of the APOE4 allele have a 12-fold increased risk of developing AD, compared with non-carriers. (cited information) |
Formal Description Interaction-ID: 71708 |
|
Comment | Ceramide levels are not significantly altered in hippocampus and temporal GM during AD pathogenesis. |
Formal Description Interaction-ID: 71710 |
disease NOT affects_quantity of drug/chemical compound |
Comment | This study demonstrates loss of S1P and sphingosine kinase activity early in AD pathogenesis, and prior to AD diagnosis. |
Formal Description Interaction-ID: 71711 |
|
Comment | SphK2 activity declines during AD pathogenesis. |
Formal Description Interaction-ID: 71712 |
disease decreases_activity of gene/protein |
Comment | S1P phosphatase (SGPP1) activity increases in temporal grey matter of AD brains. |
Formal Description Interaction-ID: 71713 |
|
Comment | S1P phosphatase (SGPP1) activity increases in temporal GM of AD brains. Despite declining SphK2 activity with increasing NFT pathology, none of SphK1, SphK2, or S1P phosphatase activity were significantly correlated with S1P/sphingosine in temporal GM (Grey Matter). |
Formal Description Interaction-ID: 71714 |
|
Comment | S1P/sphingosine ratio was 2.5-fold higher in hippocampus of ApoE2 carriers compared to ApoE4 carriers, and multivariate regression showed a significant association between APOE genotype and hippocampal S1P/sphingosine (p‚ÄČ=‚ÄČ0.0495), suggesting a new link between APOE genotype and pre-disposition to AD. |
Formal Description Interaction-ID: 71715 |
gene/protein mutant increases_activity of phenotype S1P/sphingosine ratio |
Comment | S1P/sphingosine ratio was 2.5-fold higher in hippocampus of ApoE2 carriers compared to ApoE4 carriers, and multivariate regression showed a significant association between APOE genotype and hippocampal S1P/sphingosine (p‚ÄČ=‚ÄČ0.0495), suggesting a new link between APOE genotype and pre-disposition to AD. |
Formal Description Interaction-ID: 71716 |
gene/protein mutant decreases_activity of phenotype S1P/sphingosine ratio |
Comment | Sphingosine 1-phosphate (S1P) is a potent lipid signalling molecule that associates with ApoE in high density lipoprotein (HDL) complexes in the CNS. (cited information) |
Formal Description Interaction-ID: 71717 |
drug/chemical compound interacts (colocalizes) with gene/protein |
Drugbank entries | Show/Hide entries for APOE |
Comment | Sphingosine 1-phosphate (S1P) is a potent lipid signalling molecule that associates with ApoE in high density lipoprotein (HDL) complexes in the CNS. (cited information) |
Formal Description Interaction-ID: 71718 |
drug/chemical compound interacts (colocalizes) with complex/PPI HDL |
Comment | S1P is derived by phosphorylation of sphingosine, catalysed by sphingosine kinases 1 and 2 (SphK1 and 2), and SphK1 positively regulates glutamate secretion and synaptic strength in hippocampal neurons. (cited information) |
Formal Description Interaction-ID: 80534 |
|
Drugbank entries | Show/Hide entries for |
Comment | S1P is derived by phosphorylation of sphingosine, catalysed by sphingosine kinases 1 and 2 (SphK1 and 2), and SphK1 positively regulates glutamate secretion and synaptic strength in hippocampal neurons. (cited information) |
Formal Description Interaction-ID: 80535 |
|
Drugbank entries | Show/Hide entries for |